Not once, but twice: BrainStorm shares tumble as FDA again knocks back ALS drug

The FDA was pretty clear a year and a half ago that BrainStorm Cell Therapeutics’ amyotrophic lateral sclerosis (ALS) therapy was not ready for prime time—but perhaps this latest rejection will really send the message home.